These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28547960)

  • 21. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
    Cunha LL; Marcello MA; Nonogaki S; Morari EC; Soares FA; Vassallo J; Ward LS
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):246-53. PubMed ID: 25130519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer.
    Ehlers M; Kuebart A; Hautzel H; Enczmann J; Reis AC; Haase M; Allelein S; Dringenberg T; Schmid C; Schott M
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2154-2161. PubMed ID: 27860539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using diffusion-weighted MRI to predict aggressive histological features in papillary thyroid carcinoma: a novel tool for pre-operative risk stratification in thyroid cancer.
    Lu Y; Moreira AL; Hatzoglou V; Stambuk HE; Gonen M; Mazaheri Y; Deasy JO; Shaha AR; Tuttle RM; Shukla-Dave A
    Thyroid; 2015 Jun; 25(6):672-80. PubMed ID: 25809949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma.
    Cho SW; Kim YA; Sun HJ; Kim YA; Oh BC; Yi KH; Park DJ; Park YJ
    Endocr Relat Cancer; 2016 Feb; 23(2):113-24. PubMed ID: 26559672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
    Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
    Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Papillary thyroid cancer stroma - histological and immunohistochemical study.
    Radu TG; Ciurea ME; Mogoantă SŞ; Busuioc CJ; Grosu F; Ţenovici M; Petrescu IO; Vladu IM
    Rom J Morphol Embryol; 2016; 57(2 Suppl):801-809. PubMed ID: 27833974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warthin-like papillary carcinoma of the thyroid: a case series and review of the literature.
    Erşen A; Durak MG; Canda T; Sevınç AI; Saydam S; Koçdor MA
    Turk Patoloji Derg; 2013; 29(2):150-5. PubMed ID: 23661355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications.
    Zheng X; Sun R; Wei T
    Front Immunol; 2024; 15():1438235. PubMed ID: 39290709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topographic Distribution of Papillary Thyroid Carcinoma by Mapping in Coronal Sections of 125 Consecutive Thyroidectomy Specimens.
    Mai KT; Gulavita P; Lai C; Swift J; Levac J; Olberg B; Purgina B
    Int J Surg Pathol; 2014 Jun; 22(4):303-15. PubMed ID: 24050958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
    Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
    Thyroid; 2013 Dec; 23(12):1561-8. PubMed ID: 23721357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves' Disease.
    Boutzios G; Vasileiadis I; Zapanti E; Charitoudis G; Karakostas E; Ieromonachou P; Karatzas T
    Thyroid; 2014 Feb; 24(2):347-54. PubMed ID: 23786233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome.
    Dobrinja C; Makovac P; Pastoricchio M; Cipolat Mis T; Bernardi S; Fabris B; Piscopello L; de Manzini N
    Int J Surg; 2016 Apr; 28 Suppl 1():S70-4. PubMed ID: 26708864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillary thyroid carcinoma with nodular fasciitis-like stroma: a usual entity with distinctive morphology.
    Ginter PS; Scognamiglio T
    Int J Surg Pathol; 2015 Jun; 23(4):305-7. PubMed ID: 25663334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.
    Wong KS; Strickland KC; Angell TE; Nehs MA; Alexander EK; Cibas ES; Krane JF; Howitt BE; Barletta JA
    Endocr Pathol; 2017 Jun; 28(2):171-176. PubMed ID: 28271380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical analysis of lymphocytic thyroiditis coexistent with papillary thyroid carcinoma].
    Wang SX; She ZQ; An CM; Zhang XW; Li ZJ; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 51(4):277-81. PubMed ID: 27095720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters.
    Proietti A; Ugolini C; Melillo RM; Crisman G; Elisei R; Santoro M; Minuto M; Vitti P; Miccoli P; Basolo F
    Thyroid; 2011 Nov; 21(11):1209-15. PubMed ID: 22007938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma.
    Hilly O; Rath-Wolfson L; Koren R; Mizrachi A; Hamzany Y; Bachar G; Shpitzer T
    Pathol Res Pract; 2015 Sep; 211(9):652-6. PubMed ID: 26073685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.